Want to see TXG full AI Analyst Report?
TXG Stock Chart & Stats
$26.08
-$0.12(-0.77%)
At close: 4:00 PM EST
$26.08
-$0.12(-0.77%)
Day’s Range― - ―
52-Week Range$11.16 - $46.32
Previous CloseN/A
Volume385.49K
Average Volume (3M)3.34M
Market Cap
$5.55B
Enterprise Value$2.27K
Total Cash (Recent Filing)$539.85M
Total Debt (Recent Filing)$81.39M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 06, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding116,877,320
10 Day Avg. Volume3,198,914
30 Day Avg. Volume3,339,581
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$38.22Price Target Upside46.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$613.57M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthSustained double-digit consumables growth and rising reaction volumes indicate strong recurring revenue tied to installed instruments. This pull-through model drives durable cash generation and higher lifetime value per customer, supporting long-term revenue visibility as labs continue workflows.
Strong Cash Generation & Low LeveragePositive operating and free cash flow alongside low leverage provide financial flexibility for R&D, manufacturing scale-up, and cushioning cyclical instrument demand. A resilient balance sheet reduces refinancing risk and supports strategic investments without near-term capital pressure.
Atara Product Creates Platform ExpansionAtara expands spatial whole-transcriptome capability with an upgradable roadmap, enabling higher consumables intensity per instrument and new assays. Over time this can broaden TAM, deepen customer lock-in, and generate sustained recurring revenue as adoption and downstream data demand grow.
Bears Say
Sharply Down Revenue BaseA large trailing revenue decline weakens operating leverage and limits margin expansion prospects. Even with improving gross margins and cash flow, restoring consistent top-line growth is essential for converting R&D and fixed-cost improvements into durable profitability.
Constrained Atara Supply In 2026Limited initial instrument supply delays revenue recognition and postpones the higher consumables pull-through Atara could deliver. Slower placements lengthen payback and defer broader adoption, slowing the platform's contribution to sustainable top-line and consumables growth.
Instrument Revenue Weakness & Cannibalization RiskCustomer timing shifts and platform migration can keep instrument sales depressed and create mix pressure as newer instruments may carry lower margins. Persistent instrument softness reduces expansion of the installed base and slows long-term consumables growth momentum.
TXG FAQ
What was 10X Genomics’s price range in the past 12 months?
10X Genomics lowest stock price was $11.16 and its highest was $46.32 in the past 12 months.
What is 10X Genomics’s market cap?
10X Genomics’s market cap is $5.55B.
When is 10X Genomics’s upcoming earnings report date?
10X Genomics’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were 10X Genomics’s earnings last quarter?
10X Genomics released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.175.
Is 10X Genomics overvalued?
According to Wall Street analysts 10X Genomics’s price is currently Undervalued.
Does 10X Genomics pay dividends?
10X Genomics does not currently pay dividends.
What is 10X Genomics’s EPS estimate?
10X Genomics’s EPS estimate is -0.24.
How many shares outstanding does 10X Genomics have?
10X Genomics has 116,877,320 shares outstanding.
What happened to 10X Genomics’s price movement after its last earnings report?
10X Genomics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -3.657%.
Which hedge fund is a major shareholder of 10X Genomics?
Currently, no hedge funds are holding shares in TXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.22 (46.56% Upside)
$38.22 (46.56% Upside)
Blogger Sentiment
Neutral
TXG Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
251.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
10X Genomics
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
TXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China

TXG Stock 12 Month Forecast
Average Price Target
$38.22
▲(46.56% Upside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―
Ownership Overview
2.48% Insiders
26.59% Mutual Funds
0.49% Other Institutional Investors
44.83% Public Companies and
Individual Investors









